Respicardia Revenue and Competitors
Estimated Revenue & Valuation
- Respicardia's estimated annual revenue is currently $26.9M per year.
- Respicardia received $58.5M in venture funding in December 2017.
- Respicardia's estimated revenue per employee is $251,000
- Respicardia's total funding is $160.2M.
Employee Data
- Respicardia has 107 Employees.
- Respicardia grew their employee count by 8% last year.
Respicardia's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Research/Development | Reveal Email/Phone |
2 | VP Marketing | Reveal Email/Phone |
3 | Director Medical Education and Training | Reveal Email/Phone |
4 | Sr Manager | Reveal Email/Phone |
5 | Office Manager | Reveal Email/Phone |
6 | Account Manager | Reveal Email/Phone |
7 | Consultant | Reveal Email/Phone |
Respicardia Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $43.1M | 221 | -18% | $38.2M | N/A |
What Is Respicardia?
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remed® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular healthone breath at a time.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals$160.2M
Total Funding
107
Number of Employees
$26.9M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Respicardia News
Medtronic, Respicardia Inc., Inspire Medical Systems, Siesta Medical Inc., LivaNova PLC, and LinguaFlex. Key Benefits For Stakeholders.
Sleep Apnea Implants Market Key Players- Inspire Medical Systems, Respicardia, Inc., Medtronic Plc, LinguaFlex LLC, Siesta Medical, Inc.
At Versant, he invested in a number of Minnesota companies like Metavention, Respicardia and Monteris Medical. Vensana, however, isn't ...
A new study of Respicardia's Remede central sleep apnea (CSA) implant showed long-term safety and sustained improvement in sleep metrics ...
“We're honored to continue supporting Respicardia in bringing their therapy to market,” said Tony Gonzalez, president of Integer's Cardiac ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15.8M | 109 | -6% | N/A |
#2 | $36M | 109 | -4% | N/A |
#3 | $7.5M | 112 | 11% | N/A |
#4 | $16.2M | 112 | N/A | N/A |
#5 | $32.8M | 113 | 26% | N/A |
Respicardia Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2014-07-14 | $2.0M | Undisclosed | Article | |
2014-10-30 | $20.0M | Undisclosed | Sorin Group | Article |
2017-12-19 | $58.5M | Undisclosed | ZOLL Medical Corporation | Article |